HC Wainwright Predicts Lower Earnings for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Research analysts at HC Wainwright decreased their FY2027 earnings per share estimates for shares of Xeris Biopharma in a research note issued on Monday, November 11th. HC Wainwright analyst O. Livnat now forecasts that the company will earn $0.19 per share for the year, down from their previous estimate of $0.27. HC Wainwright currently has a "Buy" rating and a $6.60 target price on the stock. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.40) per share.

Separately, Piper Sandler cut shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 target price on the stock. in a report on Monday.

Xeris Biopharma Stock Down 4.6 %

Shares of NASDAQ XERS traded down $0.15 during trading on Tuesday, reaching $3.13. The company had a trading volume of 2,531,332 shares, compared to its average volume of 1,722,042. Xeris Biopharma has a 12-month low of $1.46 and a 12-month high of $3.64. The stock has a market cap of $466.37 million, a PE ratio of -6.80 and a beta of 2.70. The business's 50-day moving average is $2.97 and its 200 day moving average is $2.51.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of XERS. Vanguard Group Inc. increased its position in Xeris Biopharma by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company's stock valued at $16,810,000 after purchasing an additional 519,897 shares during the period. SG Americas Securities LLC raised its holdings in Xeris Biopharma by 188.5% during the third quarter. SG Americas Securities LLC now owns 60,202 shares of the company's stock worth $172,000 after purchasing an additional 39,335 shares in the last quarter. Simplicity Wealth LLC purchased a new position in Xeris Biopharma during the second quarter worth $27,000. Bayesian Capital Management LP purchased a new position in shares of Xeris Biopharma in the 1st quarter worth about $37,000. Finally, Renaissance Technologies LLC grew its stake in Xeris Biopharma by 33.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company's stock valued at $3,041,000 after purchasing an additional 342,300 shares in the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.